Role of Biomarkers for the Management of Crohn’s Disease
Patients with CD in symptomatic remission
Recommendation 1
In patients with CD in symptomatic remission, the AGA suggests a monitoring strategy that combines biomarkers and symptoms, rather than relying on symptoms alone.
( Low , Conditional (weak) )Comment: Patients who place a higher value on avoiding the burden of biomarker testing, over a potentially higher risk of flare and disease progression caused by missing subclinical inflammation, may reasonably choose interval symptom-based monitoring.
Implementation considerations:
Interval biomarker monitoring may be performed every 6–12 mo in patients in symptomatic remission.
Biomarker-based monitoring may be particularly useful in patients w biomarkers have historically correlated with endoscopic disease activity
Patients with symptomatically active CD
Recommendation 5
Implementation considerations:
- Interval biomarker assessment and treatment adjustment may be performed every 2–4 mo in patients being treated for active symptoms.
- After resolution of symptoms (and normalization of biomarkers), endoscopic (and/or radiologic) evaluation should be performed to rule out active inflammation, typically 6–12 mo after treatment initiation or adjustment. The patient may then transition to guidance for patients in symptomatic remission.
Overview
Title
Role of Biomarkers for the Management of Crohn’s Disease
Authoring Organization
American Gastroenterological Association